BE2019C006I2 - - Google Patents

Download PDF

Info

Publication number
BE2019C006I2
BE2019C006I2 BE2019C006C BE2019C006C BE2019C006I2 BE 2019C006 I2 BE2019C006 I2 BE 2019C006I2 BE 2019C006 C BE2019C006 C BE 2019C006C BE 2019C006 C BE2019C006 C BE 2019C006C BE 2019C006 I2 BE2019C006 I2 BE 2019C006I2
Authority
BE
Belgium
Prior art keywords
ccr4
human
antibody
extracellular region
specifically reacts
Prior art date
Application number
BE2019C006C
Other languages
English (en)
Original Assignee
Kyowa Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Kirin Co Ltd filed Critical Kyowa Kirin Co Ltd
Publication of BE2019C006I2 publication Critical patent/BE2019C006I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4719—G-proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
BE2019C006C 2001-08-31 2019-04-25 BE2019C006I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001265144 2001-08-31
PCT/JP2002/008828 WO2003018635A1 (fr) 2001-08-31 2002-08-30 Anticorps greffes cdr humains et fragments de ces anticorps

Publications (1)

Publication Number Publication Date
BE2019C006I2 true BE2019C006I2 (fr) 2021-11-22

Family

ID=19091652

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2019C006C BE2019C006I2 (fr) 2001-08-31 2019-04-25

Country Status (23)

Country Link
US (8) US7504104B2 (fr)
EP (1) EP1449850B9 (fr)
JP (1) JP4052515B2 (fr)
KR (1) KR100959248B1 (fr)
CN (1) CN100430420C (fr)
AT (1) ATE490277T1 (fr)
AU (1) AU2002338015B8 (fr)
BE (1) BE2019C006I2 (fr)
BR (1) BRPI0212266B8 (fr)
CA (1) CA2458627C (fr)
CO (1) CO5560582A2 (fr)
CY (2) CY1111193T1 (fr)
DE (1) DE60238503D1 (fr)
DK (1) DK1449850T3 (fr)
ES (1) ES2356190T3 (fr)
FR (1) FR19C1028I2 (fr)
HK (1) HK1073851A1 (fr)
LU (1) LUC00116I2 (fr)
MX (1) MXPA04001894A (fr)
NL (1) NL300985I2 (fr)
NO (1) NO334858B1 (fr)
PT (1) PT1449850E (fr)
WO (1) WO2003018635A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2270148A3 (fr) * 1999-04-09 2011-06-08 Kyowa Hakko Kirin Co., Ltd. Méthode de régulation de l'activité d'une molécule immunologiquement fonctionnelle
CA2401491C (fr) 2000-03-03 2011-07-05 Kyowa Hakko Kogyo Co., Ltd. Anticorps fixateur ccr4 et ses utilisations diagnostiques et therapeutiques
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
AU2003211550A1 (en) * 2002-02-28 2003-09-09 Kyowa Hakko Kogyo Co., Ltd. Diagnostics and remedies for interstitial pneumonia
WO2003084569A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition anticorps
EP3006463A1 (fr) 2003-10-01 2016-04-13 Kyowa Hakko Kirin Co., Ltd. Procédé de stabilisation d'anticorps et préparation d'anticorps de type solution stabilisée
JPWO2005035582A1 (ja) * 2003-10-08 2007-11-22 協和醗酵工業株式会社 Ｃｃｒ４に特異的に結合する抗体組成物
EP1702625B1 (fr) 2003-12-04 2010-11-03 Kyowa Hakko Kirin Co., Ltd. Medicament contenant un anticorps genetiquement modifie contre le recepteur r4 de chimiokine cc
PL1703893T3 (pl) * 2003-12-23 2012-09-28 Genentech Inc Nowe przeciwciała anty-IL 13 i ich zastosowania
US20060034841A1 (en) * 2004-06-07 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Method of depleting regulatory T cell
US8329178B2 (en) 2005-02-18 2012-12-11 Dana-Farber Cancer Institute, Inc. Antibodies against CXCR4 and methods of use thereof
US20070172476A1 (en) * 2005-07-28 2007-07-26 Kyowa Hakko Kogyo Co., Ltd. Method of treating B-cell neoplasms or Hodgkin's lymphoma
US20080118978A1 (en) 2006-04-28 2008-05-22 Takashi Sato Anti-tumor agent
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
US8962806B2 (en) * 2007-12-28 2015-02-24 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
JP5552630B2 (ja) * 2008-10-24 2014-07-16 学校法人 聖マリアンナ医科大学 Ｈｔｌｖ−ｉ関連脊髄症を治療または予防するための医薬、およびｈｔｌｖ−ｉ関連脊髄症の患者に対する抗体療法の効果を試験する方法
GB0909906D0 (en) 2009-06-09 2009-07-22 Affitech As Antibodies
ES2502541T3 (es) * 2009-09-10 2014-10-03 Kyowa Hakko Kirin Co., Ltd. Medicamento que incluye una composición de anticuerpos unida específicamente al receptor 4 de quimiocina CC humana (CCR4)
CN102863533B (zh) * 2010-06-21 2013-12-11 中国科学技术大学 抗体人源化改造方法
EA201370030A1 (ru) 2010-08-10 2013-06-28 Амген Инк. Бифункциональный количественный анализ in vitro связывания мишени для обнаружения нейтрализующих антител к антителам-мишеням
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
US10266599B2 (en) 2010-12-07 2019-04-23 Cancer Research Technology Limited Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
JP6005657B2 (ja) 2010-12-16 2016-10-12 ジェネンテック， インコーポレイテッド Ｔｈ２阻害に関連する診断及び治療
ES2758884T3 (es) 2011-06-24 2020-05-06 Stephen D Gillies Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas
MX365592B (es) 2012-07-06 2019-06-07 Univ School St Marianna Medicine Anticuerpo para reducir células infectadas con el virus de htlv-1.
JP6546178B2 (ja) 2013-09-13 2019-07-17 ジェネンテック， インコーポレイテッド 細胞株中の宿主細胞タンパク質及び組換えポリペプチド産物を検出及び定量化するための組成物並びに方法
MY176026A (en) 2013-09-13 2020-07-22 Genentech Inc Methods and composions comprising purified recombinant polypeptides
JP2017517506A (ja) 2014-05-21 2017-06-29 ファイザー・インコーポレイテッド 癌を処置するための抗ｃｃｒ４抗体および４−１ｂｂアゴニストの併用
US20180271861A1 (en) 2015-07-14 2018-09-27 Kyowa Hakko Kirin Co., Ltd. Therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
WO2017220989A1 (fr) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 et cytokines il-2
RU2020122822A (ru) 2017-12-12 2022-01-13 Макродженикс, Инк. Биспецифичные связывающие cd16 молекулы и их применение при лечении заболеваний
CN108250290B (zh) 2018-02-23 2024-03-12 上海捌加壹医药科技有限公司 Ccr4的n端重组蛋白及其用途
CN116731186B (zh) * 2023-07-07 2023-12-26 武汉爱博泰克生物科技有限公司 抗人IgG-Fc兔单克隆抗体及其制备方法、多核苷酸分子、表达载体和宿主细胞

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
US5914110A (en) 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
JPH0853355A (ja) 1994-08-12 1996-02-27 Taisho Pharmaceut Co Ltd Ｉｌ−５産生抑制剤
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
WO1997010354A1 (fr) 1995-09-11 1997-03-20 Kyowa Hakko Kogyo Co., Ltd. Anticorps de la chaine alpha du recepteur de l'interleukine 5 humaine
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
EP1030662B1 (fr) 1997-11-12 2006-08-02 F. Hoffmann-La Roche Ag Traitement des maladies immunes induites par les lymphocytes t auxiliaires de type 2
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
WO2000000219A1 (fr) 1998-06-26 2000-01-06 Chugai Seiyaku Kabushiki Kaisha Remedes contre des crises d'hypercalcemie
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
US6488930B1 (en) * 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
EP1050307A1 (fr) 1999-05-06 2000-11-08 Applied Research Systems ARS Holding N.V. Antagonistes de CCR4 contre la septicémie
CA2401491C (fr) * 2000-03-03 2011-07-05 Kyowa Hakko Kogyo Co., Ltd. Anticorps fixateur ccr4 et ses utilisations diagnostiques et therapeutiques
EP1702625B1 (fr) * 2003-12-04 2010-11-03 Kyowa Hakko Kirin Co., Ltd. Medicament contenant un anticorps genetiquement modifie contre le recepteur r4 de chimiokine cc

Also Published As

Publication number Publication date
DK1449850T3 (da) 2011-02-14
JPWO2003018635A1 (ja) 2004-12-09
US20110059524A1 (en) 2011-03-10
JP4052515B2 (ja) 2008-02-27
NO20040976L (no) 2004-06-01
ATE490277T1 (de) 2010-12-15
US7504104B2 (en) 2009-03-17
US8900584B2 (en) 2014-12-02
CY2019022I1 (el) 2019-11-27
NL300985I1 (en) 2019-05-08
US20120177643A1 (en) 2012-07-12
US10590203B2 (en) 2020-03-17
FR19C1028I1 (fr) 2019-05-17
CA2458627A1 (fr) 2003-03-06
US7842797B2 (en) 2010-11-30
LUC00116I1 (fr) 2019-05-02
WO2003018635A1 (fr) 2003-03-06
EP1449850B1 (fr) 2010-12-01
US20150315285A1 (en) 2015-11-05
PT1449850E (pt) 2011-02-02
US20180030146A1 (en) 2018-02-01
MXPA04001894A (es) 2005-09-08
NO334858B1 (no) 2014-06-23
US20090227012A1 (en) 2009-09-10
KR100959248B1 (ko) 2010-05-26
KR20040044492A (ko) 2004-05-28
US10131711B2 (en) 2018-11-20
BR0212266A (pt) 2004-10-19
DE60238503D1 (de) 2011-01-13
US20030175273A1 (en) 2003-09-18
BRPI0212266B8 (pt) 2021-05-25
US8143058B2 (en) 2012-03-27
CN100430420C (zh) 2008-11-05
EP1449850B9 (fr) 2011-05-11
LUC00116I2 (fr) 2019-12-27
CA2458627C (fr) 2013-09-10
US9051371B2 (en) 2015-06-09
CY1111193T1 (el) 2015-06-11
CO5560582A2 (es) 2005-09-30
EP1449850A4 (fr) 2005-08-10
FR19C1028I2 (fr) 2021-02-19
ES2356190T3 (es) 2011-04-05
US20130273038A1 (en) 2013-10-17
CN1575303A (zh) 2005-02-02
NL300985I2 (en) 2019-11-21
HK1073851A1 (en) 2005-10-21
AU2002338015B2 (en) 2008-02-07
AU2002338015B8 (en) 2008-03-20
EP1449850A1 (fr) 2004-08-25
CY2019022I2 (el) 2019-11-27
BRPI0212266B1 (pt) 2020-05-05
US20140186349A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
NL300985I2 (en) mogamulizumab
WO2004050016A3 (fr) Administration d'agents pharmaceutiques par l'intermediaire du recepteur humain de l'insuline
EP1238985A4 (fr) Anticorps humain de transplantation d'une region de determination de la complementarite agissant contre le ganglioside gd3, et derives dudit anticorps
HUP0303952A2 (hu) Terápiás ágens gyermekkori krónikus artrítiszhez hasonló betegségekre
NO332893B1 (no) Anvendelse av antistoff for fremstilling av medikament til anvendelse ved CVP-kjemoterapi
TW224428B (fr)
TR200001891T2 (tr) ASPB28- İnsan ensülini ve kullanımı.
WO2001026693A3 (fr) Production de conjugues d'agents therapeutiques de polyglutamate
WO2003009815A3 (fr) Compositions et procedes de modulation du transport a travers la barriere hematho-encephalique
MXPA05005315A (es) Dispositivos medicos que incorporan rapamicina deuterizada para la administracion controlada de la misma.
AU2002231691A1 (en) Novel medicament compositions based on anticholinesterase drugs and on ciclesonides
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
EP1702625A4 (fr) Medicament contenant un anticorps genetiquement modifie contre le recepteur r4 de chimiokine cc
ATE327772T1 (de) Therapeutische und diagnostische ligandensysteme mit transportmolekülbindenden eigenschaften und diese enthaltende arzneimittel
AU1951195A (en) Combinations of thrombolytically active proteins and anticoagulants, and uses thereof
HU9301253D0 (en) Medical preparative applicable for treatment of enlarged time of coagulation
MXPA04002510A (es) Combinacion de opioides selectos con antagonistas de muscarina para tratamiento de incontinencia urinaria.
ES2080037T1 (es) Medicamento de uso topico con actividad cicatrizante.
AU2003290015A1 (en) Mastitis treatment
ATE271852T1 (de) Verbesserte inhalationspräparate
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.
WO2000061171A3 (fr) Nouvelles utilisations de la proteine ox2 de mammifere et reactifs associes
TR200202110T2 (tr) "5-[{6-(2-Flüore benzil) oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri"
WO1999064065A3 (fr) Therapie anti-tumorale et imagerie des tumeurs
WO2002082077A3 (fr) Production d'anticorps monospecifiques polyclonaux contre les variants upar del4, del5 et dl4+5, et leur utilisation a des fins de diagnostic et therapeutiques